{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:34Z","timestamp":1792013914986,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jaut.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T18:45:23Z","timestamp":1494009923000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Ustekinumab for Beh\u00e7et's disease"],"prefix":"10.1016","volume":"82","author":[{"given":"Adrien","family":"Mirouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Beno\u00eet","family":"Monfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Resche-Rigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Bouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clo\u00e9","family":"Comarmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"S\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Ferfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jaut.2017.05.002_bib1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2017.05.002_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00002281-200101000-00004","article-title":"Beh\u00e7et disease","volume":"13","author":"Yazici","year":"2001","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2017.05.002_bib3","first-page":"399","article-title":"A\u00a0double blind study of colchicine in Beh\u00e7et's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jaut.2017.05.002_bib4","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A\u00a0double-blind trial of colchicine in Beh\u00e7et's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2017.05.002_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.jaut.2017.05.002_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Behcet's syndrome: effects on long-term prognosis","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2017.05.002_bib7","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"issue":"16","key":"10.1016\/j.jaut.2017.05.002_bib8","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome-a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2017.05.002_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2007.06.006","article-title":"Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275","volume":"247","author":"Reddy","year":"2007","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2017.05.002_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.autrev.2014.12.009","article-title":"IFN-\u03b1 induces IL-10 production and tilt the balance between Th1 and Th17 in Beh\u00e7et disease","volume":"14","author":"Touzot","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jaut.2017.05.002_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/s10165-009-0246-1","article-title":"Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Beh\u00e7et's disease","volume":"20","author":"Habibagahi","year":"2010","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2017.05.002_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jbspin.2014.10.008","article-title":"Clinical significance of serum interleukin-23 and A\/G gene (rs17375018) polymorphism in Beh\u00e7ets disease: relation to neuro-Beh\u00e7et, uveitis and disease activity","volume":"82","author":"Gheita","year":"2015","journal-title":"Jt. Bone Spine"},{"issue":"4 Suppl 60","key":"10.1016\/j.jaut.2017.05.002_bib13","first-page":"S16","article-title":"Imbalance of Th17 to Th1 cells in Beh\u00e7et\u2019s disease","volume":"28","author":"Kim","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2017.05.002_bib14","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et's disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.jaut.2017.05.002_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","article-title":"Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et's disease susceptibility loci","volume":"42","author":"Mizuki","year":"2010","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.jaut.2017.05.002_bib16","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Investigative Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jaut.2017.05.002_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol. JEADV"},{"issue":"8","key":"10.1016\/j.jaut.2017.05.002_bib18","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J.\u00a0Rheumatol."},{"issue":"5804","key":"10.1016\/j.jaut.2017.05.002_bib19","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Sci. (New York, N.Y.)"},{"issue":"9625","key":"10.1016\/j.jaut.2017.05.002_bib20","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.jaut.2017.05.002_bib21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaut.2017.05.002_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9664","key":"10.1016\/j.jaut.2017.05.002_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"9894","key":"10.1016\/j.jaut.2017.05.002_bib24","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaut.2017.05.002_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"20","key":"10.1016\/j.jaut.2017.05.002_bib26","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jaut.2017.05.002_bib27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2017.05.002_bib28","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/sj.jid.5701140","article-title":"Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort","volume":"128","author":"Smith","year":"2008","journal-title":"J.\u00a0Investig. Dermatol."},{"issue":"8","key":"10.1016\/j.jaut.2017.05.002_bib29","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/ard.2008.090142","article-title":"Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis","volume":"68","author":"Hollis-Moffatt","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2017.05.002_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134632","article-title":"Interleukin-23 receptor gene polymorphism may enhance expression of the IL-23 receptor, IL-17, TNF-\u03b1 and IL-6 in Behcet's disease","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jaut.2017.05.002_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117301427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117301427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:16:03Z","timestamp":1760256963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841117301427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"alternative-id":["S0896841117301427"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2017.05.002","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ustekinumab for Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}